The University of Southampton
University of Southampton Institutional Repository

Identification of natural Zika virus peptides presented on the surface of paediatric brain tumour cells by HLA class I

Identification of natural Zika virus peptides presented on the surface of paediatric brain tumour cells by HLA class I
Identification of natural Zika virus peptides presented on the surface of paediatric brain tumour cells by HLA class I

Despite decades of research, survival from brain cancer has scarcely improved and is drastically lower than that of other cancers. Novel therapies, such as immunotherapy, hold great promise for treating brain tumours and are desperately needed. Zika virus (ZIKV) infects and kills aggressive cancer cells with stem-like properties (CSCs) from both paediatric and adult brain tumours. Whilst T cell recruitment into ZIKV-infected brain tumours is becoming well documented, the specific mechanisms through which they are activated are poorly understood. We address this by employing a combined global proteome and immunopeptidome mass spectrometry approach to describe, for the first time, human leukocyte antigen (HLA) presentation of ZIKV peptides on the surface of infected brain tumour cells. We first show that antigen processing and presentation by HLA class I (HLA-I) is the top enriched immune response pathway in the global proteome of aggressive paediatric USP7-ATRT brain tumour cells following ZIKV infection. We identify USP7-ATRT cells as a desirable immunopeptidome model as they express the globally common HLA-A allotype (A*02:01). We predict the majority of our 19 identified ZIKV peptides to strongly bind and be presented by HLA-A*02:01. We observe a trend between immunopeptide presentation and cellular ZIKV protein abundance, with nearly half of the peptides arising from the most abundant viral protein; non-structural protein 3 (NS3). We show the ZIKV NS3 helicase domain to be a particularly rich source of peptides. Finally, we verify that the 19 ZIKV peptides identified here are not predicted to mimic peptides of the human proteome. The ZIKV peptides we identify here are novel targets for immunotherapy, and our findings provide potential insight into the efficacious cytotoxic T cell response that oncolytic ZIKV virotherapy can induce against brain tumours.

Antigen Presentation/immunology, Brain Neoplasms/immunology, Cell Line, Tumor, Child, Histocompatibility Antigens Class I/immunology, Humans, Peptides/immunology, Proteome, Viral Proteins/immunology, Zika Virus Infection/immunology, Zika Virus/immunology
1932-6203
e0335726
Sherwood, Matt
ab7f0d51-aebb-4dc6-9b81-7904c1ef7c9b
Nicholas, Ben
01cab7d7-32c0-413f-804b-d4133070268b
Bailey, Alistair
19a50642-79ab-4760-b367-fafd3fccdf01
Mitsugi, Thiago Giove
bbb4290c-980a-459f-94d8-5021b4c42abe
Kaid, Carolini
290160fb-4f2e-4326-9a07-3a05db3dff35
Okamoto, Oswaldo K.
ddfc4523-4997-4a91-99fe-a998210efa21
Skipp, Paul
1ba7dcf6-9fe7-4b5c-a9d0-e32ed7f42aa5
Ewing, Rob M.
022c5b04-da20-4e55-8088-44d0dc9935ae
Sherwood, Matt
ab7f0d51-aebb-4dc6-9b81-7904c1ef7c9b
Nicholas, Ben
01cab7d7-32c0-413f-804b-d4133070268b
Bailey, Alistair
19a50642-79ab-4760-b367-fafd3fccdf01
Mitsugi, Thiago Giove
bbb4290c-980a-459f-94d8-5021b4c42abe
Kaid, Carolini
290160fb-4f2e-4326-9a07-3a05db3dff35
Okamoto, Oswaldo K.
ddfc4523-4997-4a91-99fe-a998210efa21
Skipp, Paul
1ba7dcf6-9fe7-4b5c-a9d0-e32ed7f42aa5
Ewing, Rob M.
022c5b04-da20-4e55-8088-44d0dc9935ae

Sherwood, Matt, Nicholas, Ben, Bailey, Alistair, Mitsugi, Thiago Giove, Kaid, Carolini, Okamoto, Oswaldo K., Skipp, Paul and Ewing, Rob M. (2025) Identification of natural Zika virus peptides presented on the surface of paediatric brain tumour cells by HLA class I. PLoS ONE, 20, e0335726. (doi:10.1371/journal.pone.0335726).

Record type: Article

Abstract

Despite decades of research, survival from brain cancer has scarcely improved and is drastically lower than that of other cancers. Novel therapies, such as immunotherapy, hold great promise for treating brain tumours and are desperately needed. Zika virus (ZIKV) infects and kills aggressive cancer cells with stem-like properties (CSCs) from both paediatric and adult brain tumours. Whilst T cell recruitment into ZIKV-infected brain tumours is becoming well documented, the specific mechanisms through which they are activated are poorly understood. We address this by employing a combined global proteome and immunopeptidome mass spectrometry approach to describe, for the first time, human leukocyte antigen (HLA) presentation of ZIKV peptides on the surface of infected brain tumour cells. We first show that antigen processing and presentation by HLA class I (HLA-I) is the top enriched immune response pathway in the global proteome of aggressive paediatric USP7-ATRT brain tumour cells following ZIKV infection. We identify USP7-ATRT cells as a desirable immunopeptidome model as they express the globally common HLA-A allotype (A*02:01). We predict the majority of our 19 identified ZIKV peptides to strongly bind and be presented by HLA-A*02:01. We observe a trend between immunopeptide presentation and cellular ZIKV protein abundance, with nearly half of the peptides arising from the most abundant viral protein; non-structural protein 3 (NS3). We show the ZIKV NS3 helicase domain to be a particularly rich source of peptides. Finally, we verify that the 19 ZIKV peptides identified here are not predicted to mimic peptides of the human proteome. The ZIKV peptides we identify here are novel targets for immunotherapy, and our findings provide potential insight into the efficacious cytotoxic T cell response that oncolytic ZIKV virotherapy can induce against brain tumours.

Text
journal.pone.0335726 - Version of Record
Available under License Creative Commons Attribution.
Download (1MB)

More information

Accepted/In Press date: 15 October 2025
e-pub ahead of print date: 30 October 2025
Additional Information: Copyright: © 2025 Sherwood et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords: Antigen Presentation/immunology, Brain Neoplasms/immunology, Cell Line, Tumor, Child, Histocompatibility Antigens Class I/immunology, Humans, Peptides/immunology, Proteome, Viral Proteins/immunology, Zika Virus Infection/immunology, Zika Virus/immunology

Identifiers

Local EPrints ID: 506489
URI: http://eprints.soton.ac.uk/id/eprint/506489
ISSN: 1932-6203
PURE UUID: 2db09885-2732-4b6b-a164-18856169f511
ORCID for Matt Sherwood: ORCID iD orcid.org/0000-0002-1912-9758
ORCID for Paul Skipp: ORCID iD orcid.org/0000-0002-2995-2959
ORCID for Rob M. Ewing: ORCID iD orcid.org/0000-0001-6510-4001

Catalogue record

Date deposited: 10 Nov 2025 17:40
Last modified: 11 Nov 2025 02:51

Export record

Altmetrics

Contributors

Author: Matt Sherwood ORCID iD
Author: Ben Nicholas
Author: Alistair Bailey
Author: Thiago Giove Mitsugi
Author: Carolini Kaid
Author: Oswaldo K. Okamoto
Author: Paul Skipp ORCID iD
Author: Rob M. Ewing ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×